Stroke Recovery and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains

Why this is studied in Stroke Recovery

After ischaemic stroke, some recovery happens spontaneously through oedema resolution and cortical reorganisation, mostly in the first three to six months. Cell therapy is studied both acutely for neuroprotection and chronically for plasticity support — and that spontaneous recovery window is the reason early uncontrolled results in this indication are so often misleading.

What HSCT means in this table

Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.

The numbers

Every figure below comes from one reproducible query (stroke x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

Registration activity is thin and early: 14 records in total, none at confirmatory phase, 1 recruiting.

5 records are marked completed and 1 ended early (terminated, withdrawn or suspended): 7% of registrations did not run to plan.

Median planned enrolment is 20 participants (largest single study: 63). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

6 countries host at least one site. China is the largest single contributor at roughly 54% of country mentions in this sample.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Sponsorship leans academic: 7 of the most frequent lead sponsors read as academic or hospital entities and 1 as companies. Who pays shapes what gets measured and what gets published.

• Southern Medical University, China — 3 records
• Zhejiang Hospital — 1 record
• Hokkaido University Hospital — 1 record
• Assistance Publique - Hôpitaux de Paris — 1 record
• Universidade Federal do Rio de Janeiro — 1 record
• Affiliated Hospital of Nantong University — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

Treat this as a map of research activity. It tells you whether a claim has an evidence programme behind it — not whether the treatment helped anyone.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many HSCT studies for Stroke Recovery are recruiting right now?

1 of 14 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is HSCT an approved treatment for Stroke Recovery?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 14 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on HSCT for Stroke Recovery?

0 of 14 records carry a Phase 3 or Phase 4 label and 5 are marked completed. Registrations run from 2005 to 2027.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.